Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ah ok, thanks for being honest much respect energyshares. Still a good find from you and a good write up who ever the mystery person is. Makes a very valid assumption that Moderna could have taken Affimer into a human trial using AVA004.
avacta July 2019 PDF pages 9/10 seems to confirm what the write up is implying… wonder who the mystery writer is, it’s like a mystery within a mystery!?
Just got home reading posts.
Jay Kay’s that’s not my thesis, I just found it on the internet and shared with the board.
energyshares great mini thesis, and detective work.
https://avacta.com/wp-content/uploads/2019/09/Avacta-Group-July-2019-16-9.pdf
Found this: on pages 9,
- title says fully funded partnerships
- shows Moderna logo on there
- showing Moderna timeline you have pointed out
- AVA004 PD-1 title in Moderna bar frame timeline.
Page 10:
- first time in-human for affimer platform
- again in milestone section show same timeline of Moderna:- exercise deal right 2019/2020 ind filing/human trial H1 2021
Both pages have AVA004 PD-L1 on them.
Actually think your right in what you’ve said in your writeup. AVA004 cld be the first affimer based trials in humans, could be getting an RNS on this from Moderna.
The Moderna partnership is fully funded by them, so all hard work paid for to derisk AVA004 PD-1 and avacta tmac pipelines.
Thanks @ Energyshares for sharing not seen that informal paper before .
Moderna pipeline - mentions " Preclinical PD-L1 Autoimmune hepatitis mRNA-6981" ?
https://www.modernatx.com/pipeline
"Moderna Exercises Exclusive Product License Option Mon, 4th Feb 2019 "
"Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies."
https://www.lse.co.uk/rns/AVCT/moderna-exercises-exclusive-product-license-option-u8uij5azn3xterf.html
Difficult to say what the target might be perhaps still be in discovery stage , Moderna not mentioned in Avacta latest business review however did get a very small mention mentioned in annual accounts .
"A research collaboration and option agreement to develop Affimer®molecules against oncology targets that can be encoded as mRNA and expressed directly from human tissue"
However postive that Moderna did exercise " Product License Option Mon, 4th Feb 2019 " guess depends on Moderna priorities on progress made ?
I like your thinking, ES. Thanks for sharing.
Moderna would not be the only partner working with Affimers against PD-L1. LG Chem are confirmed to be developing a PD-L1 Affimer (could be AVA004, could be a different Affimer against the same target) using the XT serum to extend half-life, and have exclusive rights for that combination.
AS has said that Avacta are not looking to compete directly against existing drugs with Affimers that perform the same function (eg AVA004 vs Keytruda or similar), but to use them instead to do novel things you can’t do so easily with antibodies, eg TMAC, multi-specifics, etc. I think that’s why AVA004/Affimers against PD-L1 as a monotherapy are instead being pushed by external collaborators (LG Chem), while Avacta focus on combining them with PreCISION and a chemo warhead to create TMAC. mRNA coding of them would be a third application - maybe others yet to come?
The LG Chem development, if/when it gets to clinical trials, could be the key to unlock these other applications of AVA004/PD-L1 Affimers - as well as Affimers in humans more generally, just as the AVA6000 trials are the key to unlocking the whole preCISION platform. These two drug developments are absolutely massive for Avacta.
thanks. Don't understand everything but certainly interesting. If Moderna have exclusive right to AVA4000 it would explain why Avacta not pushing it, and letting them do the heavy lift.
some way off, and hopefully brought to market with enough time on patent.
If a specific affimer is used for this purpose, can it be patented separately eg affirmer X = use 1, affirmer Y = use 2 ?
There’s a lot of pent up news to come from Avacta, don’t give up on LFT’s sales they’re happening, so are things regarding the many partnerships that have been set up around the world. The only thing that’s holding back the SP is the lack of news flow. Come on Dr Al, give us some meaty news before Christmas. GLA
Brilliant thesis ES, thanks a lot!
AVA004 is potentially a dark horse in the Avacta pipeline!
Bumped for a worthwhile second read.
Wiggly: I have been thinking exactly these thoughts for a while now, hence my fairly relaxed attitude towards an overly large holding. He quite obviously knows a lot more than he is letting on IMHO.
Plenty of fish in this sea!
I hope so Energy. The fact that Avacta and AS appear to be relaxed about the current share price does lead me to speculate that bigger things are at play in the background.... If not I do believe that AS would be much more active with comms related to managing the share price / attracting new investment (as he did during the dev of the LFT).
While Avacta have many known projects cooking there is a reasonable potential for a new wild cat deal that takes the market by surprise.
Great post energy shares. Thank you. The therapeutics excite me, that’s why I am long on Avacta.
Could this be the Moderna golden ticket.
Avacta has so many shots on goal…..
https://www.yumpu.com/en/document/read/63845056/potential-target-for-moderna-avacta-collaboration